secwatch.observer — SEC 8-K summary
======================================

Issuer:     Forte Biosciences, Inc. (FBRX)
CIK:        0001419041
Form:       8-K
Filed at:   2026-04-09T23:59:59+00:00
Accession:  0001193125-26-148796
Event type: other_material
Sentiment:  neutral
Materiality: 0.85
Item codes: 1.01, 7.01, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Forte Biosciences prices $150M public offering of 5.7M shares at $26.27/share
-----------------------------------------------------------------------------

- Pricing of 5,709,936 shares at $26.27 per share for gross proceeds of ~$150M.
- Underwriters have 30-day option to buy up to 856,490 additional shares.
- Offering expected to close April 10, 2026; net proceeds ~$141M.
- Proceeds to fund working capital and clinical development of autoimmune product candidate.
- Strategic investment from argenx BV noted; Guggenheim and Barclays are joint book-runners.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1419041/000119312526148796/0001193125-26-148796-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1419041/000119312526148796/d128424d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-26-148796

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer